Spyre Therapeutics, Inc.

Signal Note: Baker Bros. Initiates $32.8B Position in Spyre Therapeutics (SYRE)

Note: The reported position value of $32.76B on 1M shares appears to be a data error — SYRE's entire market cap is ~$3.3B; this likely represents a ~$32.8M position, consistent with shares at ~$32.76/share.

That said, Baker Bros. initiating any new position in Spyre is a meaningful signal. Spyre is developing next-gen anti-TL1A (izalontafig) and anti-TNF (lusacaftor) antibodies for IBD (ulcerative colitis and Crohn's disease), directly competing in the hot anti-TL1A space against Merck's tulisokibart. Key catalysts include Phase 2 readouts for izal

Signal Note: Driehaus Capital Initiates $94.4M Position in Spyre Therapeutics

Driehaus's entry into SYRE (2.88M shares) signals confidence in Spyre's pipeline, likely driven by upcoming clinical catalysts in its lead program for systemic sclerosis-associated interstitial lung disease (SSc-ILD), a high-unmet-need indication with limited approved therapies. The ~$94M position size suggests conviction ahead of Phase 2 data readouts expected in 2024-2025, though investors should monitor for efficacy/safety risks common in fibrotic lung disease programs.